RT Journal Article
SR Electronic
T1 Comparison of the Immunogenicity of five COVID-19 vaccines in Sri Lanka
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.15.21267834
DO 10.1101/2021.12.15.21267834
A1 Chandima Jeewandara
A1 Inoka Sepali Aberathna
A1 Saubhagya Danasekara
A1 Laksiri Gomes
A1 Suranga Fernando
A1 Dinuka Guruge
A1 Thushali Ranasinghe
A1 Banuri Gunasekera
A1 Achala Kamaladasa
A1 Heshan Kuruppu
A1 Gayasha Somathilake
A1 Jeewantha Jayamali
A1 Deshni Jayathilaka
A1 Helanka Dinesh Kumara Wijayatilake
A1 Pradeep Darshana Pushpakumara
A1 Michael Harvie
A1 Thashmi Nimasha
A1 Shiromi Devika Grace de Silva
A1 Ruwan Wijayamuni
A1 Lisa Schimanski
A1 Pramila Rijal
A1 Jack Tan
A1 Alain Townsend
A1 Graham S. Ogg
A1 Gathsaurie Neelika Malavige
YR 2021
UL http://medrxiv.org/content/early/2021/12/15/2021.12.15.21267834.abstract
AB We assessed antibody responses 3 months post-vaccination in those who received mRNA-1273 (n=225), Sputnik V (n=128) or the first dose of Gam-COVID-Vac (n=184) and compared the results with previously reported data of Sinopharm and AZD1222 vaccinees. 99.5% of Moderna >94% of AZD1222 or Sputnik V, 72% to 76% of Gam-COVID-Vac (first dose) and 38.1% to 68.3% of Sinopharm vaccinees had ACE2 blocking antibodies above the positive threshold. The ACE2 blocking antibody levels were highest to lowest was Moderna > Sputnik V/ AZD1222 (had equal levels)> first dose of Gam-COVID-Vac > Sinopharm. All Moderna recipients had antibodies above the positive threshold to the ancestral (WT), B.1.1.7, B.1.351.1 and 80% positivity rate for B.1.617.2. Positivity rates of Sputnik V vaccinees for WT and variants, were higher than AZD1222 vaccinees, while Sinopharm vaccinees had the lowest positivity rates (<16.7%). These findings highlight the need for further studies to understand the effects on clinical outcomes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe are grateful to the Allergy, Immunology and Cell Biology Unit, University of Sri Jayewardenepura; the NIH, USA (grant number 5U01AI151788-02), UK Medical Research Council and the Foreign and Commonwealth Office for support. T.K.T. is funded by the Townsend-Jeantet Charitable Trust (charity number 1011770) and the EPA Cephalosporin Early Career Researcher Fund. A.T. are funded by the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Science (CIFMS), China (grant no. 2018-I2M-2-002).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics approval was obtained from the Ethics Review Committee of University of Sri Jayewardenepura.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript.